This consortium establishes a national academic infrastructure called NL-OPENSCREEN open to the Dutch life science community. Through NL-OPENSCREEN we will make small-molecule libraries and screening facilities available for high throughput and cell based testing against bio-molecular targets of scientific interest. Optimization programs will be provided, in which hit-structures are developed by chemical modification. This provides new and enabling research tools for fundamental biological and biomedical studies, as well as for further development into drug candidates.
Computational methods are routinely used in drug discovery and lead optimization projects. Within NL-OPENSCREEN ample expertise is available in the application of computational chemical biology (‘big data approaches’) and cheminformatics.
NL-OPENSCREEN has assembled ample expertise to add precise pharmacological texture to the screening results, by integrating ligand engagement / target binding kinetics into the various screening protocols.
NL-OPENSCREEN will assist users with the translation of bench-top assays into assay suitable for high-throughput or phenotypic screening.
Pivot Park Screening Centre accelerates drug discovery by using their long expertise on (u)HTS and their state-of-the-art robotic equipment to run screens in 384 or 1536-well format on a high quality compound library.
NL-OPENSCREEN will assemble high-quality targeted/focused compound libraries aimed at specific target protein families that will provide higher success rates.
Screen the cellular phenotypes of compound libraries in multiple dimensions.
Activity-based proteome profiling (ABPP) is an attractive and powerful chemical biological technique that accelerates most stages of the drug discovery process.
NL-OPENSCREEN is an integral part of the pan-European EU-OPENSCREEN network.